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United Kingdom. E-mail: v.khutoryanskiy@reading.ac.uk; Tel: +44(0)1183786119 4 
Abstract:  5 
Various strategies for ocular drug delivery are considered; from basic formulation techniques for 6 
improving availability of drugs; viscosity enhancers and mucoadhesives aid drug retention and 7 
penetration enhancers promote drug transport into the eye. The use of drug loaded contact lenses 8 
and ocular inserts allows drugs to be better placed where they are needed for more direct 9 
delivery. Developments in ocular implants gives a means to overcome the physical barriers that 10 
traditionally prevented effective treatment. Implant technologies are under development allowing 11 
long term drug delivery from a single procedure, these devices allow posterior chamber diseases 12 
to be effectively treated. Future developments could bring artificial corneas to eliminate the need 13 
for donor tissue and one-off implantable drug depots lasting the patient’s lifetime. 14 
Key Terms  15 
Bandage contact lens: Device designed to fit directly onto the front of the eye to offer 16 
protection during the healing process, for example, after corneal surgery. 17 
Container molecule: Molecular structures with cavities that can accommodate another molecule 18 
via guest – host complexation. 19 
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Hydrotrope: Water-soluble compound that improves the aqueous solubility of hydrophobic or 20 
poorly water-soluble compounds.  21 
In situ gelling system: Liquid formulations that turn in to gel upon dosage form administration. 22 
These phase transitions can typically be triggered by changes in temperature, pH or electrolyte 23 
interaction. 24 
Mucoadhesive: Defined as a compound, usually a polymer, with the ability to adhere to mucosal 25 
tissue.  26 
Ocular insert: A drug-loaded device designed to reside within the ocular cul-de-sac, attach to 27 
the conjunctiva or directly onto the cornea. 28 
Ocular implant:  Dosage forms implanted directly into the ocular globe; these can be devices 29 
that bring ‘quality of life benefit’ such as intraocular lenses used for crystalline lens replacement. 30 
Implantable devices are also used for sustained and controlled drug delivery to the posterior 31 
segment.    32 
‘Smart’ DDS: Responsive drug delivery systems where a favourable change takes place in 33 
response to some form of stimulus, for example, change in temperature, pH, ionic interactions or 34 
stimulation from a light source. 35 
 Introduction 36 
Ocular drug delivery is hampered by the physiological barriers presented by the eyes. These 37 
include, blinking and wash out by tears, nasolacrimal drainage, non-productive losses and 38 
impermeability of the cornea. [1,2]  39 
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Some of the various structures of the eye are detailed in Figure 1, highlighting the intricate 40 
complexity of this organ. The conjunctiva (not shown for clarity) is the mucosa lining the inside 41 
surface of the eyelids and the external surface of the front of the eye up to the limbus, the edge of 42 
the cornea. 43 
 44 
 45 
Figure 1.  A sketch showing some of the key features of the human eye. 46 
Despite the easy accessibility of the eye for administering medication, in many ways it is an 47 
isolated organ with several barriers imposing challenges to drug delivery, tear mechanisms, the 48 
physical barriers of its membranes, blood-aqueous and blood-retinal barriers.[3] 49 
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Topical, systemic and intraocular are the three main routes for administering ophthalmic 50 
medication; each has their own advantages and disadvantages. Topical drug delivery is the most 51 
accepted route accounting for ~90% aqueous ophthalmic formulations. Advantages are their 52 
relative simplicity to formulate, minimal storage limitations and ease of drug instillation by most 53 
patients. Disadvantages include limited drug concentration for lipophilic agents, pre-corneal 54 
losses and the barrier function of the cornea.[4,5] For effective systemic delivery a relatively 55 
high drug concentration needs to be circulating in the blood plasma in order to achieve a 56 
therapeutically effective dose within the eye. Sustained release oral drugs can be suitable for 57 
glaucoma patients, allowing for continuous and effective treatment, however this method 58 
exposes the whole body to the drug often giving rise to undesired side effects.[6]  Intraocular 59 
drug delivery by intravitreal injection is an invasive procedure carrying a degree of risk such as 60 
retinal hemorrhage or detachment, especially if the technique needs to be repeated when treating 61 
chronic disorders.  However, it is very effective at getting drugs to the posterior segment.[3] 62 
The cornea is the main route for topically applied drugs to gain access into the eye and the 63 
conjunctival/scleral route can also be efficient. [7,8] Drops are the most accepted means to apply 64 
medication to this organ;[9] they are easy to apply by most patients and they are convenient. 65 
However, regardless of the ease of access to the eye for topical application of medication, 66 
efficient ocular drug delivery is hampered by a series of clearance mechanisms that protect the 67 
ocular structures from foreign matter.  Upon administration of traditional eye drops they are 68 
immediately diluted in the tear film followed by very quick elimination by action of blinking, 69 
wash out by tears, and nasolacrimal drainage. [10,11] After instilling eye drops, there remains a 70 
very short time where any residual medication is in contact with the cornea during which time 71 
there is opportunity for the drug to penetrate into the eye; however, due to poor corneal 72 
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permeability only a very small portion of active pharmaceutical ingredient will be capable of 73 
crossing the cornea. Of the applied dose, only 1% or less will successfully reach the intended 74 
target in most cases, the rest will be systemically absorbed via the conjunctiva or nasolacrimal 75 
mucosa to be eliminated by metabolic processes.[5] The tear film comprises of several 76 
compartments, Figure 2 shows the 3 layer tear film model comprising of a coating of mucous 77 
anchored to the epithelium via microvilli, an aqueous compartment containing soluble mucin and 78 
free lipid and a thin lipid layer [11-14].  79 
 80 
 81 
Figure 2.  The 3 layer tear film model.  82 
The tear film and ocular mucosa are the first external barriers to overcome, after which the 83 
multilayered structure of the cornea (Figure 3) offers the next challenge; this structure has both 84 
lipophilic and hydrophilic properties and there are 5 distinct layers: Epithelium, Bowman’s 85 
membrane, stroma, Descemet’s membrane and endothelium.[6,15]  The first corneal layer is the 86 
epithelium which is ~50 μm at its center increasing to ~100 μm at the limbus; this layer is 87 
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lipophilic, offering ~90% resistance to hydrophilic drugs and ~10% to hydrophobic preparations.  88 
Immediately underneath the epithelium is the Bowman’s membrane, a transitional acellular 89 
structure ~8-14 μm in thickness.  Next we find the hydrophilic stroma; this is a gel-like structure 90 
with around 80 % water, consisting of collagen, mucopolysaccharides and proteins and it forms 91 
the main bulk of the cornea, some 90 % of its total thickness. Next there is the Descemet’s 92 
membrane, a tough membrane of around 6 μm thickness supporting the endothelium, a single 93 
layer of loose, epithelia-like cells important in regulating stromal hydration, and this layer is 94 
deposited by endothelial cells. The correct level of hydration is important for the cornea to 95 
remain clear and transparent.[6,15,16]  96 
 97 
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 98 
Figure 3.  Micrograph of a section of bovine cornea showing the multi-layered structure typical 99 
of mammalian corneas.  Scale bar = 100 μm.  100 
The corneal epithelial barrier also has different zones; the basement layer consists of newly 101 
formed cells firmly attached to the Bowman’s layer, here they are columnar in shape. As new 102 
cells are formed the preceding basement cells are pushed forwards, becoming polyhedral in 103 
shape, eventually as they are moved towards the corneal surface where they become polygonal 104 
squamous cells. These superficial epithelial cells have Ca
2+
 dependent membrane adherent 105 
regions; zonula occludens, zonula adherens and desmosomes forming tight junctions.[17]   106 
Taken together, these tightly bound cell membrane regions and the lipophilic nature of the 107 
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epithelium make the structure an extremely efficient barrier that resists intrusion of foreign 108 
material including potentially therapeutic compounds; this creates a major challenge for ocular 109 
drug delivery.[6,11,18]  110 
Strategies for enhancing ocular drug delivery 111 
Despite traditional eye drops being convenient and simple to use, they are not very efficient and 112 
only a small amount of the dose is effectively delivered to its intended target, most is lost due to 113 
clearance mechanisms. There are however certain strategies that can be employed to improve the 114 
bioavailability of drugs.  First, solubility enhancers can be used, to improve drug concentrations 115 
within the formulation; more medication in the dosage form can mean increased bioavailability. 116 
This strategy could allow a smaller droplet to be applied, which would be less susceptible to loss 117 
by drainage due to induced reflex tearing and blinking.[6]  Second, the formulation can be 118 
designed in a form that resists clearance; these dosage forms are retained for a longer period, 119 
therefore they have more time to interact with ocular tissue.  Next, drug penetration enhancers 120 
can be incorporated into the formulation to assist their transit across the cornea.[19]  Ocular 121 
inserts are another area of active research and development. With this method a drug-loaded 122 
device resides in the cul-de-sac under the eyelids or fits directly on the cornea like a contact lens; 123 
these devices are often designed with controlled release in mind.[20,21] Drug delivery into the 124 
cornea and anterior chamber is difficult enough; delivering an effective therapeutic dose to the 125 
posterior segment is a major challenge, in many cases it is not possible to deliver sufficient 126 
medication to the posterior structures via the topical route.[22]  For diseases of the retina, such as 127 
age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa and 128 
related ocular neovascular disease there is often a  need to resort to invasive methods for drug 129 
delivery.  Angiogenesis inhibitor medication via intravitreal injection is an option for getting 130 
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drugs to the posterior segment but these are often effective for the short term and need repeat 131 
injections, which carries risks such as hemorrhage, endophthalmitis, ocular hypertension and 132 
retinal detachment.[22-26]  Ocular implants are devices that penetrate the sclera or reside within 133 
the deeper ocular structures to deliver drugs for an extended period, sometimes many years, 134 
minimising the need for repeat injections.[23]  Implantable devices that are not designed to 135 
deliver drugs are also employed to improve the ‘quality of life’ for patients with certain 136 
conditions, for example, intraocular lenses.  However, drugs to counter postoperative bacterial 137 
infection are often included in these devices for short term protection.[27,28] These various 138 
strategies will be discussed in more detail in the following sections. 139 
Solubility enhancers: 140 
Discovery of potentially therapeutic compounds is accelerating through developments in 141 
genomics, combinational chemistry and the ability to use high throughput screening.  High 142 
proportions of newly screened compounds prove to be hydrophobic and are poorly water-143 
soluble.[29] For efficacious performance in the physiological environment drug candidates need 144 
to interact within an aqueous media, the interstitial fluids within tissues.   145 
Drugs used for treatment of ocular disorders often have low aqueous solubility and eye drops are 146 
only in contact with ocular tissue for a short time. Formulations that are developed to increase 147 
the amount of available drug in solution could improve its bioavailability, therefore solubility 148 
enhancement is an important strategy to use when developing ocular medication. Solubility 149 
enhancement can be achieved by employing hydrotropic compounds.  Evstigneev et al.[30] and 150 
Coffman and Kildsig [31,32] reported the effectiveness of caffeine, urea and nicotinamide and its 151 
derivatives as efficient hydrotropes for enhancing the solubility of riboflavin, a vitamin with poor 152 
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aqueous solubility of less than 0.1 mg mL
-1
 which is used as a photosensitive drug for the 153 
treatment of keratoconus.  Cyclodextrins  are a class of cyclic supramolecular compounds that 154 
have been well studied for dissolution enhancement of low solubility drugs; Loftsson and 155 
Stefansson discussed the use of cyclodextrins for complexation with steroids, carbonic anhydrase 156 
inhibitors, pilocarpine and cyclosporins in eye drop formulations which are well tolerated.[33] 157 
Morrison et al.[34]  investigated cyclodextrins for their hydrotropic properties and were able to 158 
show that β-cyclodextrin achieved solubility enhancement of more than 140% for riboflavin. 159 
Whilst the above mentioned studies achieved modest solubility enhancements, research by Kim 160 
et al. [29] investigating the performance of two hydrotropes; N,N-diethylnicotinamide (DENA) 161 
and N,N-dimethylbenzamide (DMBA) with 13 poorly water-soluble drugs and these compounds 162 
were shown to have superior hydrotropic action between 1000- to 10000- fold.  163 
Supramolecular structures are sub-micron sized molecules within the realm of nanotechnology 164 
and many of these assemblies have solubility enhancement properties.  This technology is 165 
becoming an important tool within the pharmaceutical industry with substantial investment 166 
within the global market. Dendrimers, microemulsions, nanoparticles, nanosuspensions and 167 
liposomes belong to this class of compound and are proving to be useful structures to improve 168 
bioavailability, all of which are at the forefront of research in ocular drug delivery.[1,2,35-41]  169 
Micelles are aggregates of amphiphilic molecules forming self-assembled spheres in aqueous 170 
media. They have a monolayer ‘shell’ of polar groups with their associated fatty acid ‘tails’ 171 
forming the core. These are useful carriers of hydrophobic drugs within the core albeit with 172 
limited efficiency due to a high amphiphile / drug ratio.[42]  The work of Qu et al.[43] involved 173 
chemical modification of chitosan by increasing their hydrophobicity and this allowed them to 174 
produce 100 – 300 nm sized micellar clusters which could achieve up to an order of magnitude 175 
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enhancement in hydrophobic drug bioavailability compared to micelles produced using triblock 176 
copolymers.  In ocular drug formulations they were able to show an initial prednisolone 177 
concentration in the aqueous humor equivalent to that found when using a 10-fold dose of 178 
prednisolone suspension.  179 
An approach taken by Kulkarni et al. [44] was to take the poorly soluble drug, indomethacin, and 180 
using simple chemistry, convert this drug into its sodium salt. They found that this improved its 181 
aqueous solubility and the drug was stable at physiological pH and compatible with excipients 182 
used for ocular drug formulation.  183 
Penetration enhancement: 184 
Materials that modify the corneal epithelia can allow enhancement of drug permeation and this 185 
can be achieved using various strategies. Benzalkonium chloride (BAC) is commonly used as a 186 
preservative in ocular drug formulations, this together with other compounds; cetylpyridinium 187 
chloride (CPC), ethylenediaminetetraacetic acid (EDTA), polyoxyethylene strearyl ether (PSE) 188 
and polyethoxylated castor oil (PCO) are compounds with penetration enhancing properties. 189 
Their mode of action is due to destabilisation of the tear film and the protection given by its 190 
mucus component (for BAC), and ultrastructural alterations [17] and solubilisation of cellular 191 
membranes for the other enhancers. Useful as they are for penetration enhancement they can also 192 
induce irritation and damage to ocular epithelium even at low concentrations. Chung et al. [45] 193 
and Burgalassi et al. [46] investigated these materials confirming their irritation and cytotoxicity 194 
effects.  Liu et al. [47] state that penetration enhancers should be: 195 
 Non-toxic; 196 
 Non-irritant to the eye; 197 
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 Inert and compatible to other excipients within the formulation; 198 
 Fast acting  and reversible action; 199 
 Effective at low concentration.  200 
In their report they discuss the use of several penetration enhancers for ocular drugs; BAC, 201 
EDTA, surfactants, heteroglycosides, bile salts, polycarbophil-cysteine conjugates and boric 202 
acid, all of which have been used in ophthalmic formulations despite the fact that even at low 203 
concentrations they can cause ocular irritation.[47] Morrison et al. [17] investigated drug 204 
penetration enhancement using EDTA and two analogues EGTA and EDDS and they found that 205 
this was achieved by sequestering Ca
2+
 and therefore loosen tight junctions which depend on the 206 
availability of these ions.  207 
Gelucires are glycerides composed of mono-, di- and triglycerides with mono- and diesters of 208 
polyethylene glycol.  They are amphiphilic with surface active properties.[48] Gelucire 44/14 has 209 
a melting temperature of 44°C and a hydrophilic – lipophilic balance of 14, hence its name. It is 210 
a compound  known for its permeation enhancing properties and is ‘generally regarded as safe’ 211 
(GRAS). Liu et al. [47] investigated Gelucire 44/14 for its permeability enhancing performance 212 
in vitro and in vivo for various ophthalmic drugs and demonstrated that it enhanced transcorneal 213 
permeability of drugs with a range of hydrophilicity / lipophilicity whilst remaining non-214 
irritating. Loftsson and Stefansson [33] reviewed cyclodextrins  for enhanced topical delivery of 215 
steroids for ophthalmic formulation and the cyclodextrin-drug complexes were found to be well 216 
tolerated in eye drop formulations.  Cyclodextrins and their drug complexes are too large to 217 
partition into the cornea and until recently it was generally thought that they kept the drug in 218 
solution at the eye surface where the drug was able to diffuse into the tissue,[47,49] or by 219 
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modulation of the aqueous diffusion layer on the corneal surface.[50]  Morrison et al. [34] 220 
investigated the use of cyclodextrins as ocular drug delivery excipients for permeability 221 
enhancement of riboflavin for the treatment of keratoconus.  They have shown that cyclodextrin 222 
forms complexes with riboflavin and release their drug payload by preferential take up of 223 
cholesterol from corneal epithelial cell membranes. The removal of cholesterol renders the 224 
epithelium permeable, allowing enhanced drug penetration. Figure 4 shows β-cyclodextrin 225 
induced histological changes to the epithelium of bovine corneas (b,d,f), compared to those 226 
without cyclodextrin exposure (a,c,e). β-Cyclodextrin induced loosening of the epithelium 227 
appears to increase with exposure time of 15, 45 and 75 minutes (b,d,f respectively), and this 228 
correlates with increased riboflavin penetration without complete destruction of this barrier.  229 
  230 
Figure 4.   Micrographs of bovine cornea cross-sections showing differences between areas that 231 
were exposed to β-cyclodextrin (b,d,f) or not (a,c,e), at 15, 45 and 75 minutes. Scale bar = 100 232 
μm. Adapted with permission from: Morrison et al.[34] Cyclodextrin-mediated enhancement of 233 
riboflavin solubility and corneal permeability. Molecular Pharmaceutics. 10, 756-762  (2013). 234 
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Retention strategies: 235 
Pre-corneal losses have a major impact on ocular drug delivery; it follows that if the drug 236 
formulation stays in contact with the intended tissue for longer it is more likely to penetrate the 237 
target site to afford its desired action.  Adopting an approach for formulation retention is one 238 
way to minimize this problem and this can be achieved by several means. Various retention 239 
approaches will be discussed in the following section:  240 
Viscosity enhancing polymers; 241 
Natural and synthetic polymers prove useful for their viscosity enhancing properties in ocular 242 
drug formulations for improving residence time. These materials absorb water to form 243 
viscoelastic gels which prove to be suitable vehicles for drug delivery, and they include 244 
derivatives of cellulose, poly(vinyl alcohol), poly(vinyl pyrrolidone), carbomers (weakly 245 
crosslinked poly(acrylic acids)), and the natural mucopolysaccharide; hyaluronic acid, a 246 
component of the vitreous humour.[51,52] Mechanisms for release of incorporated drugs are 247 
determined by their chemical structure, network arrangement and swelling properties.[53]  248 
Ocular drug delivery formulations incorporating viscosity enhancing polymers resist lacrimal 249 
drainage when residing in the lower conjunctival cul-de-sac. However, disadvantages with this 250 
approach are an initial blurring of vision due to changes in refractive index at the corneal surface, 251 
and difficulty instilling a precise dose.[24,54,71] 252 
In situ gelling systems; 253 
‘In situ’ gelling systems undergo phase transition from liquid to gel under physiological 254 
conditions and this technique has advantage over the simpler viscosity enhancing systems.  Phase 255 
transition can be mediated by physiological temperature, pH or electrolyte composition at the 256 
cornea surface.  257 
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Thermogelling systems include polaxomers,[55,56] pluronics and tetronics,[57]. Ur-Rehman et 258 
al. [58] investigated combined formulations of polaxamer 407 with chitosan as thermogelling 259 
delivery systems for ocular, vaginal, orthodontal and parenteral drug administration; this process 260 
allowed site specific tunable drug delivery with enhanced gel strength and mucoadhesive 261 
properties. Gratieri et al. [59,60] also worked with polaxamer/chitosan gel forming systems, their 262 
aim was to develop phase transition gels with improved mechanical and mucoadhesive 263 
properties. They investigated poly(ethylene oxide) – poly(propylene oxide) - poly(ethylene 264 
oxide) triblock polymers (PEO-PPO-PEO) with chitosan of various polymer ratios and found 265 
that the polymer/chitosan  ratio of 16:1 w/w  offered optimum gelation temperature of 32°C,  266 
good resistance to shearing forces at 35°C and good retention due to mucoadhesion. Poly(N-267 
isopropylacrylamide) is a well-researched thermogelling polymer with a lower critical solution 268 
temperature (LCST) of 32°C, an ideal temperature for thermosensitive applications for ocular 269 
drug delivery, although the polymer precipitates above the LCST forming a stiff gel which can 270 
be uncomfortable for ocular drug delivery applications.[61]  It also shows reduced transparency 271 
above LCST,[62] which would be undesirable for eye-drop formulations. Cao et al.[61] 272 
investigated thermogelling poly(N-isopropylacrylamide)-chitosan formulation and found it to be 273 
a suitable system for ocular delivery of water-soluble drugs, but it is not clear whether they have 274 
solved the ‘reduced transparency’ issue with their development. Mayol et al. [56] investigated 275 
thermogelling polaxamers (F127 and F68) and found that on their own their gelling properties 276 
were not ideal but could be optimized by addition of the naturally occurring mucoadhesive 277 
polysaccharide, hyaluronic acid. They consider that this approach can be exploited for a range of 278 
sustained drug delivery scenarios and they are especially suited for ocular drug delivery. PH-279 
mediated systems include Carbopol®,[63] and cellulose acetate phthalate. [64] Electrolyte 280 
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triggered gelling systems make the transition from liquid to gel by induction of crosslinking in 281 
the gelling system mediated by cations present in the tear fluid, and these include gellan gum 282 
(Gelrite®), carrageenan,[65-67] and sodium alginate.[68]  283 
Mucoadhesives; 284 
Mucoadhesion is the interaction between a compound, usually a polymer, natural or synthetic, 285 
with mucosa or associated mucus.[53,69] Mucoadhesive drug delivery depends on the interplay 286 
between the dosage form and mucus covered mucosal epithelial membranes, residence time 287 
increases due to this interaction, allowing more time for the drug to penetrate its intended site of 288 
action.[69,70] Mucosal adhesion of dosage forms can be explained using a combination of 289 
theories:[71,72]  290 
 Electronic theory, where interaction is due to electron transfer between the dosage form 291 
and mucosal surface. 292 
 Adsorption theory, attraction mechanisms are via electrostatic effects, hydrogen bonds 293 
and Van der Waals forces.  Hydrophobic effects are also implicated, more so when the 294 
mucoadhesive polymers are amphiphilic.  Covalent bonding can also come into effect 295 
between some specific polymers and mucins. 296 
 Wetting theory, mostly applies to liquid mucoadhesives where there are structural 297 
similarities between the polymer and mucin, these effects reduce surface tension and 298 
allow the mucoadhesive polymer to spread on the mucosal surface. 299 
 Diffusion theory, considers the interpenetration of polymer into the mucus and diffusion 300 
of soluble mucins into the mucoadhesive. 301 
17 
 
Neither of the above mentioned theories can be used to explain mucoadhesion on their own, 302 
more, they each play a part to varying degrees within any given scenario.[71-74]  In considering 303 
a typical series of events involving a mucoadhesive – mucosa interaction; first of all the wetting 304 
theory comes into play with wetting and associated swelling of the dosage form; next physical 305 
interactions involving electronic and adsorption theories take place forming non-covalent bonds 306 
between the system components; diffusion theory then comes into play when further non-307 
covalent bonds during interpenetration of polymer-protein chains during which physical and 308 
covalent (chemical) bonds form again involving electronic and adsorption theories.[71,72]   309 
With traditional ocular drug delivery systems residence time is determined by tear turnover, but 310 
for mucoadhesive systems this becomes governed by mucus turnover, hence drug retention and 311 
bioavailability is substantially increased.[51] Mucoadhesive polymer films could potentially 312 
provide a suitable platform to deliver ocular drugs, Khutoryanskaya et al.[75] investigated the 313 
use of complexes and blends of poly(acrylic acid) (PAA) and methylcellulose (MC) to produce 314 
polymeric films as vehicles for ocular drug delivery. PAA has excellent mucoadhesive properties 315 
due to an ability to form hydrogen bonds with mucin, although it has limited application for 316 
transmucosal drug delivery due to being very hydrophilic, thus quick dissolving; it also has poor 317 
mechanical properties and can cause irritation to delicate mucosa.  MC has favourable properties 318 
that are applied in transmucosal delivery systems; it has excellent biocompatibility profiles but 319 
has poor mucoadhesive properties. The researchers used a polymer blend approach with different 320 
combinations of PAA / MC under a range of pH and optimized a formulation bringing together 321 
the favourable properties of both polymers.  In vitro studies of drug-loaded polymer films 322 
determined their release profiles and they found that films enriched in MC had significantly 323 
slower drug release profiles than films enriched in PAA.  This could allow a tunable drug 324 
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delivery system depending on whether rapid or sustained release is required.  They further 325 
investigated in vivo retention of the polymer films using rabbits and found that 100% MC films 326 
were retained for up to 50 minutes but successful application was hampered by poor 327 
mucoadhesive properties. 100% PAA films were strongly mucoadhesive but retention was poor 328 
due to quick dissolution. They concluded that polymer blends had good bioadhesive qualities and 329 
showed better retention of 30-60 minutes compared to the films composed of individual 330 
polymers. [75] 331 
Nanoparticles; 332 
Nanoparticle drug delivery systems are more generally described as submicron sized structures; 333 
these systems were described by Nagarwal  et al.[19] as 10 to 1000 nm particles in which drugs 334 
could be loaded by attachment to the matrix or dissolved within, encapsulated or entrapped 335 
within the structure giving a versatile drug delivery system.  Hans and Lowman [76] discuss 336 
biodegradable polymeric nanoparticles for drug delivery, they suggest that surface modified 337 
biodegradable solid nanoparticles have an advantage regarding controlled release, principally for 338 
targeted drug delivery for the treatment of specific organs, in particular for extended drug 339 
delivery to the cornea and conjunctiva.[76]  Ibrahim et al.[77] describe a mucoadhesive 340 
nanoparticle system as a carrier for gatafloxacin/prednisolone biotherapy for treatment of 341 
bacterial keratitis, a serious corneal condition which could lead to blindness without rapid and 342 
appropriate intervention. The drug loaded nanoparticle systems they describe were produced 343 
from Eudragit® RS 100 and RL 100 and were coated with the bioadhesive polymer hyaluronic 344 
acid.  Nanoparticles within the suspensions produced using these systems were in the range of 345 
315 nm to 973 nm.  For ocular drug delivery, supramolecular structures, complexes and 346 
composites belong to nanoparticulate systems and these can include microemulsions, liposomes, 347 
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niosomes, dendrimers and cyclodextrins.[1,2,36-41] Kassam et al.[78] investigated the use of 348 
nanosuspensions for ophthalmic delivery of three virtually insoluble glucocorticoid drugs in 349 
aqueous media; hydrocortisone, prednisolone and dexamethasone. Their findings show an 350 
enhancement to the rate and extent of ophthalmic drug absorption together with improved drug 351 
performance compared with aqueous solutions and microcrystalline suspensions.  De Campos et 352 
al.[79] investigated the interaction of poly(ethylene glycol)- or chitosan- coated colloidal 353 
nanocapsules with ocular mucosa; they conclude from ex vivo studies that the systems they 354 
developed enhanced permeation of dye through the cornea. Evidence from confocal microscopy 355 
shows their systems penetrated the epithelium of rabbit cornea via the transcellular pathway and 356 
they found that PEG-coated colloids had an enhanced rate of transport across the whole 357 
epithelium; whilst chitosan-coated nanocapsules were retained in the superficial epithelial layers. 358 
They suggest these systems could be designed as colloidal drug carriers targeting a specific 359 
purpose, that is, to attach to the cornea or penetrate into or through it. This implies these systems 360 
should prove useful of treating conditions of the cornea and deeper structures within the eye.   361 
Diseases of the posterior section of the eye include macular degeneration, diabetic retinopathy, 362 
retinitis pigmentosa and related ocular neovascular disease. Topical delivery of drugs to the 363 
posterior section of the eye is particularly challenging due not least to ocular barrier function and 364 
internal clearance mechanisms within the anterior chamber.  Recent developments in the field of 365 
nanoparticles involve submicron-sized liposomes (ssLips) and these are proving useful for 366 
topical drug delivery systems in the form of eye drops for the treatment of posterior segment 367 
diseases.  Studies by Hironaka et al. and Inikuchi et al. [80,81] show successful delivery of 368 
coumarin-6 to the retina via non-corneal and non-systemic pathways using eye drops. The 369 
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assumption can be made that posterior section delivery is via penetration through the sclera 370 
using ssLips [8,41] (emphasis highlights conclusion of the authors of this review).   371 
Ocular inserts: 372 
Ocular inserts are drug loaded devices placed in the upper or lower cul-de-sac and in some cases, 373 
directly on the cornea; their purpose is to act as a controlled release drug reservoir. These 374 
systems can be insoluble devices that need to be removed after a given period of time or they can 375 
be designed to dissolve, erode or biodegrade at the ocular surface.  Early forms of ocular inserts 376 
have been used since the middle ages and were given the arabic term al-kohl.  By the nineteenth 377 
century, paper patches soaked with drug solutions were used and in the early twentieth century 378 
glycerinated gelatin systems were in use.[82] It is not clear how effective these early devices 379 
were, however, drug delivery by this means has developed and devices can be of soluble 380 
ophthalmic drug inserts (SODI) or insoluble polymers, mucoadhesives or soluble natural 381 
materials such as collagen (e.g. from porcine sclera).[4]  Ideally these devices could be applied 382 
and left in place with no further intervention thereafter.  Ocular inserts need to be discreet and 383 
comfortable to gain patient acceptance.  Sustained release ophthalmic inserts are defined as 384 
sterile devices which can be drug impregnated thin, single or multi-layered films, solid or 385 
semisolid materials. The objective being to extend ocular contact time thus improving 386 
bioavailability.  Development of ocular inserts that bring reliable controlled release drug delivery 387 
and patient comfort offers a considerable challenge. The main classes of devices are insoluble, 388 
soluble and biodegradable inserts.[83]  Ocusert® was the first relatively successful product for 389 
delivery of pilocarpine for the treatment of ocular hypertension and has been commercialised 390 
since 1974. Ocusert® consists of a pilocarpine-alginate reservoir sandwiched between thin 391 
ethylene-vinyl acetate films, the devices are designed to deliver pilocarpine at either 20µg per 392 
21 
 
hour or 40 µg per hour.  Some disadvantages of this system were unreliable control of intraocular 393 
pressure, leakage, folding, difficulty inserting the devices and ejection or irritation.[82,84]  394 
Ocufit SR® are sustained release rod shaped devices made from silicone elastomer, designed to 395 
reside in the lower conjunctival fornix; these devices are well tolerated and expulsion is 396 
significantly less  than with oval or flat inserts. Minidisc ocular therapeutic system (OTS) by 397 
Bausch & Lomb  are drug-loaded polymer discs with similar shape as contact lenses but are 398 
smaller (4-5 mm); they were designed to reside on the sclera in the upper or lower fornix and 399 
deliver the antibiotics gentamicin or sulfisoxazole between 3-14 days depending on the system. 400 
The company produces non-erodible hydrophobic and hydrophilic systems and erodible devices 401 
based on hydroxypropyl cellulose. The inserts are comfortable and easy to use for most patients. 402 
Smith & Nephew Pharmaceutical Ltd patented what they term ‘new ophthalmic delivery system’ 403 
(NODS®); these devices offer precision pilocarpine delivery for glaucoma patients from 404 
poly(vinyl alcohol) (PVA) film flags. These devices attach to the mucosal surface of the lower 405 
conjunctival sac where it takes up fluid from the tears, swells and delivers its drug payload at a 406 
pre-determined rate into the lacrimal fluid as it slowly dissolves.[82]  Mydriasert® are insoluble 407 
devices marketed by IOLTech for the delivery of phenylephrine  and tropicamide to induce 408 
sustained mydriasis during surgery or for examination of the fundus (interior ocular surface).[3] 409 
Human amniotic membrane has been used for corneal transplant to treat corneal disorders and 410 
ulcerative ocular conditions. Resch et al. [85,86] investigated its use as drug loaded ocular 411 
devices to deliver ofloxacin in vitro and they concluded that single layer human amniotic 412 
membrane had a significant reservoir capacity capable of delivering the drug for up to 7 hours in 413 
vitro. They propose that drug pretreatment of amniotic membrane could be beneficial when using 414 
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this tissue for ocular transplant when treating infectious keratitis.[85,86]  Table 1 lists some 415 
advantages and disadvantages for using ocular  inserts. [20,82,87] 416 
Table 1.  Advantages and disadvantages using ocular inserts. 
Advantages Disadvantages 
 Increased residence time / bioavailability 
 Precision dosing with controlled release, 
avoids pulsate drug delivery 
 Minimal systemic absorption 
 Administration frequency reduced 
 Conjunctival / scleral route to internal 
target 
 Better shelf life and no preservatives 
 Combinational therapeutic approaches 
 Physical and psychological obstacles of 
placing solid objects on the eye, foreign 
body sensation 
 Movement around the eye could interfere 
with vision 
 Potential accidental loss 
 Some devices difficult to insert or 
remove 
 Potential burst release upon insertion 
prior to controlled delivery 
 417 
Recent developments in ocular insert drug delivery systems: 418 
Colo et al. [88] investigated the effect of adding chitosan hydrochloride (CH-HCl) to 419 
mucoadhesive erodible ocular inserts produced from poly(ethylene oxide) (PEO) of various 420 
molecular weight for delivery of ofloxacin.  They added 10, 20 and 30 % medicated CH-HCl 421 
microparticles to PEO formulations made from 900 kDa or 2000 kDa.  Erosion of the devices 422 
was accelerated proportional to CH-HCl content. The lower molecular weight PEO proved more 423 
suitable for prolonged drug release. They conclude that inclusion of CH-HCl in the devices aids 424 
erosion and enhances corneal permeability of ofloxacin when compared to devices not 425 
containing CH-HCl.  Hornof et al. [89] developed mucoadhesive devices based on thiolated 426 
poly(acrylic acid) (PAA) and these were evaluated in human in vivo studies. Their aim was to 427 
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develop mucoadhesive ocular inserts for controlled delivery of ophthalmic drugs using 428 
fluorescein as a fluorescent tracer to determine release rates from the devices in humans. They 429 
compared mean fluorescein concentrations in the tear film and cornea as a function of time after 430 
instillation of eye drops and inserts composed of thiolated and unmodified PAA. The thiolated 431 
polymer inserts formed a soft, insoluble hydrogel and were well tolerated by volunteers. Their 432 
findings show this material offers a promising platform for ocular drug delivery for a prolonged 433 
duration.  Mishra and Gilhotra [63] designed and characterized a bioadhesive in-situ gelling 434 
ocular insert for the delivery of gatifloxacin using a mixture of sodium alginate with chitosan, 435 
which was plasticized with glycerin.  They combined sodium alginate for its gelling properties, 436 
with chitosan for its bioadhesive qualities, formulations of various proportions were prepared 437 
and films were produced using the solvent casting technique as described by Pandit et al. [90] 438 
Using this system they found an accumulative drug release of 95-99% during 8-12 hours  and the 439 
formulation consisting of 2% alginate with 1% chitosan had the most sustained release of 12 440 
hours. They conclude that this system allowed production of uniform in situ gelling polymer 441 
films suitable for controlled release of gatifloxacin for the treatment of bacterial keratitis and 442 
conjunctivitis.[63]  Natamycin is a polyene antibiotic used for the treatment of fungal blepharitis, 443 
bacterial keratitis and conjunctivitis and it has the ability to reduce intraocular pressure. 444 
Rajasekaran et al.[91] compared the controlled release performance of natamycin from ocular 445 
inserts they designed from a variety of polymeric materials; Eudragit® L-100, S-100, RL-100, 446 
hydroxypropyl methyl cellulose phthalate (HMCP) and cellulose acetate phthalate (CAP) in 447 
different proportions with poly(ethylene glycol-400) (PEG-400) as a plasticizer. Their aim was 448 
to develop devices for in situ sustained drug delivery and their approach was to prepare 449 
polymeric films using the solvent casting method. 1 cm discs were cut from the films to be used 450 
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as inserts; these were evaluated for their physicochemical properties such as drug concentration, 451 
weight, folding durability, thickness, moisture absorption and vapour transmission rate.  FTIR 452 
studies established that there was no chemical interaction between the drug and polymers used. 453 
In vitro studies were conducted to determine their drug release kinetics; devices made from CAP, 454 
HPMCP and Eudragit® S-100 released all of their drug payload within 10-15 hours, whilst 455 
inserts  made from increased concentrations of Eudragit® RL-100 continued release for 18-23 456 
hours; best performance was shown for formulations consisting of 3% Eudragit® RL-100 and 457 
1% Eudragit® L-100. They conclude that nataycin loaded ocular inserts produced from 3% 458 
Eudragit® RL-100 and 1% Eudragit® L-100 plasticised with 33% PEG-400 are capable of 459 
controlled drug delivery  up to 23 hours. 460 
Contact lenses for drug delivery  461 
Contact lenses are hard or soft polymeric devices designed to fit directly onto the cornea to 462 
correct refractive abnormalities; they can be produced from hydrophilic or hydrophobic 463 
polymers. Hydrogel contact lenses are realistic products to act as ocular drug delivery systems; 464 
they are able to imbibe a large volume of aqueous solution relative to their anhydrous form. If 465 
the aqueous solution that hydrates the contact lens contains sufficient pharmaceutically active 466 
material this will be able to diffuse from the polymer matrix into the tear film bathing the eye 467 
and subsequently interact with the ocular tissue. However, there still remains a need to retain the 468 
drug within the devices sufficiently to provide sustained release. 469 
The idea of using hydrogel contact lenses as drug delivery devices was first suggested by 470 
Wichterle et al. [29,92] in their 1965 patent, in which they suggest the inclusion of medication 471 
upon lens hydration to offer extended drug availability during wear.  Contact lens design 472 
determines how they are to be used; daily, weekly and monthly disposable options are 473 
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available.[92]  Early approaches to contact lens aided drug delivery relied on absorbance of drug 474 
loaded solution during pre-wear soaking.  Conventional contact lenses have limited drug loading 475 
potential and drug delivery using this method proves unreliable, giving an initial ‘burst release’ 476 
followed by rapid decline over a relatively short period.[20,93]  Other methodologies include 477 
molecular imprinting technology, drug loaded coating or addition of a sandwhich layer of drug-478 
loaded polymer, inclusion of drug-loaded nanoparticles and cyclodextrin grafting.[28]  479 
Molecular imprinting technology is a technique whereby the polymer formulation is modified to 480 
give it a higher affinity towards drug molecules, thus increasing their drug loading potential and 481 
prolonging delivery [94-96].  Hiratani et al. [93] took this approach in developing a system 482 
employing methacrylic acid, N,N-diethylacrylamide and the drug timolol; from this system they 483 
were able to achieve sustained timolol release for almost 48 hours in vitro.  Alvarez-Lorenzo et 484 
al. [97] applied the same strategy to produce norfloxacin-loaded poly(hydroxyethyl 485 
methacrylate) contact lenses and they report that reservoir capacity was enhanced by up to 300 486 
fold compared with pHEMA lenses without molecular imprinting technology. Hyatt et al.[98] 487 
investigated the release profiles of gentamicin and vancomycin from fibrin coated and fibrin 488 
sandwiched contact lenses in vitro; their aim was to develop a system that could offer controlled 489 
and sustained drug delivery for a minimum period of 8 hours.  They conclude that the fibrin 490 
gel/lens systems performed better for extended delivery of gentamicin compared to normal 491 
lenses soaked with the antibiotic solution, however, their performance for delivering vancomycin 492 
was poor compared to soaked lenses. Lenses incorporating fibrin showed potential for treating 493 
microbial keratitis.  Ciolino et al.[99,100] investigated poly(lactic-co-glycolic acid) (PLGA) 494 
coatings and sandwiched films with contact lenses as potential drug delivery devices. They found 495 
that contact lenses incorporating PLGA film retained antifungal properties up to 3 weeks in vitro, 496 
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and their prototype ciprofloxacin eluting contact lens demonstrated controlled release at 497 
therapeutically active concentrations for up to 4 weeks in vitro.  Although fibrin or PLGA film 498 
sandwiched and coated lenses bring sustained drug delivery benefits, the lenses are opaque; 499 
therefore they require clear ‘window’ in the centre of the lens allowing the patient to see during 500 
treatment.[97-100] Inclusion of drug loaded nanoparticles within the polymer matrix of contact 501 
lens is an effective strategy for prolonged drug delivery. This approach can allow sustained 502 
release which can be tuned towards the patient’s needs, anything between a few hours to several 503 
weeks.  Gulsen and Chauhan [101] conducted a pilot study to determine the effectiveness of 504 
nanoparticle laden pHEMA.  The nanoparticles were based on oil-in-water microemulsion 505 
loaded with lidocaine, a hydrophobic drug; the droplets were then encapsulated in a silica shell 506 
which stabilized the nanoparticles and these were incorporated in the hydrogel matrix during 507 
polymerization. Hydrophobic lidocaine has a slight and finite solubility in water; therefore it is 508 
able to slowly diffuse from the nanoparticles into the aqueous phase of the gel matrix where it 509 
would then be able to further diffuse into the tear film.  The nanoparticle-laden hydrogels 510 
remained clear and drug release studies in vitro showed an initial burst release followed by slow 511 
and steady release thereafter; by day 10 virtually all the drug had been released.  They conclude 512 
that the nanoparticle-loaded hydrogels could be suitable for controlled drug delivery for several 513 
days at therapeutically effective concentrations.  Gulsen and Chauhan [102] followed up their 514 
previous investigation of nanoparticle-laden pHEMA by developing four more microemulsion 515 
based formulations, type 1 and 2 were based on canola oil with Tween® 80 and Panadon SDK, 516 
with or without a stabilizing silica shell, and type 3 and 4 were based on hexadecane with Brij® 517 
97 with or without a stabilizing silica shell; they incorporated lidocaine as a model drug.  Type 1 518 
formulation was opaque due to the poor solubility of Tween® 80 in HEMA, type 2 formulation 519 
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lost some transparency but was not opaque indicating that the silica shell reduced interaction 520 
between the surfactant and HEMA.  Type 3 showed minimal transparency reduction but was not 521 
as transparent as pHEMA, type 4 showed no observable loss of transparency due to stabilization 522 
afforded by the silica shell.  Release studies in vitro determined that formulations based on 523 
hexadecane with Brij® 97 were suitable for sustained drug delivery at therapeutic rates for up to 524 
8 days, Tween®80 based formulation was deemed unsuitable due to poor stability and particle 525 
aggregation. Gulsen and Chauhan speculate that furthering this work to develop ‘smart’ 526 
particulate based systems which could respond to pH or temperature change could minimise 527 
burst release and decaying release rates.[101,102]  The approach followed by Jung and Chauhan 528 
[103] was to develop a timolol loaded nanoparticle / HEMA based contact lens system. Their 529 
aim was to produce nanoparticles without using surfactant due to opacity issues when these are 530 
used with HEMA. Using thermal polymerization techniques they formed drug loaded 531 
nanoparticles based on crosslinking monomers; propoxylated glycerol triacrylate (PGT) and 532 
ethylene glycol dimethacrylate (EGDMA) and incorporated these in pHEMA hydrogels. Their 533 
product was a transparent drug loaded hydrogel with temperature dependent release rates 534 
between 2-4 weeks. They conclude their system maintains drug stability under refrigerated 535 
conditions and the temperature change promotes drug release upon insertion of the lenses into 536 
the eyes. Figure 5 shows how nanoparticles could release entrapped drug molecules into the pre- 537 
and post-tear films. 538 
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 539 
Figure 5.   Drug diffusion from nanoparticles encapsulated within hydrogel contact lens.  The 540 
scale used in this image has been exaggerated for clarity. 541 
Drug loading capacity of hydrogel contact lenses can be enhanced by the inclusion of ‘container 542 
molecules’. Cyclodextrins, with their ‘guest-host’ properties have been investigated for this 543 
purpose.  Complexation between cyclodextrins and drug molecules is a dynamic process due to 544 
the weak non-covalent interactions in play.  The strategy followed by dos Santos et al.[104] was 545 
to synthesise methacrylated β-cyclodextrin and use it to form co-polymer with HEMA and 546 
EGDMA, the polymers formed had clear gel properties. Drug loading was achieved by soaking 547 
the anhydrous polymers in solutions of acetazolamide or hydrocortisone for 4 days.  The 548 
performance of these methacrylated β-cyclodextrin hydrogels was studied in vitro and they were 549 
found to offer tunable drug loading/release rates with capacity for sustained drug delivery over 550 
several days.  They followed up this study with development of another hydrogel formulation 551 
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using β-cyclodextrin grafted onto pHEMA-co-GMA (glycidyl methacrylate).  This system was 552 
able to enhance diclofenac loading by 1300% and could sustain drug release for 2 weeks in 553 
lacrimal fluid.  They conclude that these systems could have potential for pharmaceutical 554 
applications in soft contact lenses and other medicated devices.[105]  Xu et al.[106] produced 555 
hydrogel films and contact lenses from  HEMA, mono-methacrylated β-cyclodextrin and 556 
trimethylolpropane trimethacrylate.  Puerarin was incorporated as a model drug by soaking in 557 
drug solution to hydrate the gel. In vitro studies determined loading and release rates were 558 
dependent on β-cyclodextrin content.  In vivo studies using rabbits showed the gels offered 559 
sustained drug release with superior performance compared to commercial puerarin eyedrops.  560 
The devices had excellent mechanical properties and the researchers propose the material is 561 
suitable for drug delivery from re-usable daily wear contact lenses.  562 
Ocular implants: 563 
Treating the posterior segment 564 
Historically, the posterior segment has been exceptionally difficult to treat due to the many 565 
barriers that obstruct ingress of foreign matter into the eye. The development of ocular implants 566 
have allowed these external barriers to be overcome. Modern devices allow long term treatments 567 
for otherwise impossible to treat conditions, many devices provide medication for years from a 568 
single procedure. [107,112] 569 
Drug eluting intraocular lenses 570 
Intraocular lens (IOL) surgery is a well-established and safe procedure routinely performed 571 
worldwide; however as with any surgical technique there is always risk from infection or other 572 
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complications, for example, postoperative inflammation, posterior capsule opacification (PCO) 573 
and secondary cataracts caused by epithelial cell adhesion and proliferation in the posterior lens 574 
capsule. Introduction of preventative medication during surgery is subject to decay or 575 
elimination before it can be effective.  Much research is currently carried out for development of 576 
drug eluting IOL’s to minimise postoperative problems, and also to address concurrent 577 
pathologies. IOL / drug combinations can be achieved by pre-insertion soaking in concentrated 578 
drug solution (only useful for drugs with a high affinity for the polymer), coating with layers of 579 
drug/polymer, chemical grafting of drugs, drug impregnation using super critical fluids and 580 
attaching inserts onto the haptics (the ‘arms’ of the IOL).[28] A study by Kleinmann et al.[113] 581 
determined that commercial hydrophilic acrylic lenses (C-flex, Rayner intraocular lenses) [114] 582 
have affinity for fourth generation fluoroquinolones and were able to release this drug above the 583 
minimum inhibitory concentration in rabbits for at least 12 hours.  They conclude C-flex/drug 584 
combination is safe and effective for delivery of these antibiotics.  Davis et al.[115] investigated 585 
concentrations of 4 antibiotics (moxifloxacin, gatifloxacin, linezolid and ceruroxime) in aqueous 586 
and vitreous humour samples from rabbit eyes. Drug released from implanted hydrophilic IOL’s 587 
was analysed using HPLC to determine drug concentration in the ocular fluid samples. The 588 
IOL’s used were STAAR Nanoflextm Colamer®, 40% water content material comprised of a 589 
collagen, pHEMA blend,[116] pre-soaked in antibiotic solution.  Ocular fluid samples were 590 
taken for analysis at intervals up to 24 hours. It was established that the antibiotics studied were 591 
above the minimum inhibitory concentration in the aqueous humour for at least 6 hours, notably, 592 
gatifloxacin concentrations remained above this level at 24 hours after implantation.[116]  593 
Layer-by-layer deposition is a technique used for coating opposing charge polymers to rigid 594 
hydrophobic IOL’s, a drug can be incorporated during this process. Coating pHEMA based 595 
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hydrophilic IOL’s by immersion in octadecyl isocyanate can be an effective method to give 596 
controlled release from norfloxacin containing IOL’s.  Grafting drug molecules onto the IOL 597 
surface can provide a permanently active surface to prevent cell adhesion, or allow release of 598 
drugs by some external trigger, for example light irradiation. High drug concentrations within a 599 
polymeric matrix can be achieved using supercritical CO2 as a means to force drugs into the 600 
polymer without the need for organic solvent.[28]  Duarte et al.[117] employed supercritical CO2 601 
technology to impregnate p(MMA-EHA-EGDMA), a suitable polymer for IOL manufacture, 602 
with flurbiprofen, an anti-inflammatory drug used for intraocular delivery.  Their experiments 603 
found the process allowed higher drug impregnation and release studies showed the system to be 604 
effective for up to 3 months.  The approach employed by Garty et al. [27] was to produce 605 
norfloxacin loaded pHEMA cylinders in 1.0 mm diameter microglass tubes with 0.09 mm 606 
stainless steel wire through the centre during room temperature polymerization. When fully 607 
polymerized the hydrogel was ejected from the tube and the wire removed leaving a tubular 608 
hydrogel structure, this was washed with sterilized water to remove unreacted components. The 609 
gel was cut into 1.0 mm lengths and lyophilized. Next they added a hydrophobic coating using 610 
octadecyl isocyanate to control drug release. The devices were used as sleeves placed over IOL 611 
haptics and this assembly was used in lens replacement procedures in the rabbit model.  Results 612 
from in vivo studies showed the devices offered sustained drug delivery above the minimum 613 
inhibitory concentration for over 4 weeks. They conclude that these controlled release devices 614 
are effective at sustained delivery of therapeutic levels of drugs within the anterior chamber post 615 
operatively. Incorporation of drugs with IOL’s has predominantly aimed at postoperative 616 
delivery of antibiotics and anti-inflammatory medication.  617 
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Drug delivery by intravitreal injection 618 
There are many debilitating and sight threatening conditions resulting from posterior segment 619 
diseases and in most cases the only way these can be treated is by invasive procedures, for 620 
example ‘intravitreal injection’. In the main this still remains so, however, developments have 621 
brought a diverse range of effective implantable drug delivery systems targeting posterior 622 
segment disease and the various options will now be considered. [22] The most common means 623 
to place drugs in the posterior chamber employs injection into the vitreous humour; this provides 624 
a high concentration of drug where it is needed and minimises systemic complications. Xu et al. 625 
investigated the diffusion of polystyrene nanoparticles of various size and surface chemistries in 626 
fresh bovine vitreous and they were able to achieve tuneable drug transport within the posterior 627 
chamber depending the designed properties of the nanoparticle [118]. However, many conditions 628 
require repeated treatment and this can cause intraocular problems, for example, cataract, retinal 629 
detachment, haemorrhage, endophthalmitis and ocular hypertension.  630 
Intraocular implants 631 
In an attempt to overcome the problem of frequent injections biodegradable and non-632 
biodegradable drug depot devices which can offer long term drug release into the posterior 633 
chamber have been developed and further research in this area is ongoing. Solutions, liposomes, 634 
micelles, nanoparticles and vectosomes are suitable for intravitreal injection although these 635 
dosage forms only give short term drug availability, generally days to several weeks.[23,119]  636 
Biodegradable and non-biodegradable drug depot devices have been developed and further 637 
research in this area is ongoing.  Implantable devices for long term drug delivery are on the 638 
market or currently undergoing clinical trial.  Vitrasert® is a drug depot device for sustained 639 
delivery of ganciclovir via a rate limiting poly(vinyl acetate)/ethylene vinyl acetate (PVW/EVA) 640 
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membrane for up to 8 months.[22,119,120]  Retisert® intraocular inserts were approved by the 641 
FDA in 2005. They are inserts for delivery of the corticosteroid, fluocinolone acetonide for 642 
treatment of posterior uveitis, a serious sight threatening condition.  The devices are designed for 643 
long term drug release up to 30 months.[121] Vitrisert® and Retisert® inserts are non-644 
degradable and require surgical implantation and removal.[22] Medidur® are implantable 645 
devices for delivering fluocinolone acetonide for up to 36 months. This device consists of a 646 
narrow cylindrical polyimide tube loaded with the drug and PVA-based end caps provide rate 647 
limiting drug delivery. The 3.5 mm long device is inserted through a 25-g needle carried out 648 
under local anaesthesia and creates a self-healing wound eliminating the need for surgery.[122]  649 
Implants employing biodegradable polymers are promising systems for intraocular drug delivery. 650 
Sivaprasad et al. [123] report the use of the Posurdex® biodegradable polymer device for 651 
treatment of macula oedema using dexamethasone. This drug has a half-life of less than 24 hours 652 
therefore it provides only limiting management of this condition by injecting the drug.  However, 653 
dexamethasone containing Posurdex® devices were shown to deliver the drug at a constant rate 654 
for up to 4 months, these devices have been re-named Ozurdex® and are marketed by Allergan 655 
Inc. [124]  In vivo studies using monkeys showed the system was effective at reducing retinal 656 
vasculopathy and neuropathy.[125]  Surodex® is a poly(lactic-glycolic acid) device to be 657 
inserted in the anterior or posterior chamber at the time of cataract surgery to deliver 658 
dexamethasone for up to 10 days.  Tan et al. [126] conducted a randomized clinical trial to 659 
evaluate the effectiveness of the Surodex® insert as a safe and effective treatment of intraocular 660 
inflammation in post-cataract surgery. Their study employed flare meter readings to determine 661 
inflammation and this showed that measured values were lower in all readings from the 662 
Surodex® group compared to those treated post operatively with dexamethasone eye drops, they 663 
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conclude that implantation of a single Surodex® device at the time of cataract surgery reduces 664 
post-surgery inflammation [126,127]. 665 
Future perspectives: 666 
In this review the various strategies for enhancing bioavailability of ophthalmic drugs have been 667 
considered; how drug bioavailability can be improved using solubility, retention and 668 
permeability enhancers has been explored. Drug loaded contact lenses allow localised delivery 669 
directly to the cornea, where the lenses offer controlled release whilst isolating the post corneal 670 
tear film from lachrymal clearance. Nanoparticle technology is allowing drug delivery to the 671 
posterior chamber via topically applied formulations. Future research is likely to bring 672 
discoveries of materials with superior performance compared with those in current use. 673 
The use of ocular inserts for extended and intimate contact between the dose form and ocular 674 
tissue proves to be a beneficial strategy and the use of ocular implants allows all external barriers 675 
to be overcome, giving direct access to internal tissues whilst minimising side effects.  Many of 676 
these approaches have been developed in recent decades and continue to be improved upon with 677 
new innovations.  Looking to the future innovative advances to delay or prevent blindness could 678 
be made; developments in two main areas could be speculated; the cornea and vitreous humour. 679 
First, corneal disease has a major influence on visual health; corneal tissue engineered constructs 680 
are being developed to test new ocular drugs. Future development of artificial corneas could 681 
become a possibility to replace diseased ones without the need for donor tissue, which is a scarce 682 
commodity.[127,128] Another area for advanced drug delivery is the posterior segment; 683 
vitrectomy is an invasive but well-established procedure for many posterior segment disorders. A 684 
synthetic material is used to replace natural vitreous humour.  The possibility of developing 685 
synthetic materials for whole or partial vitrectomy as a drug depot could allow long term 686 
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controlled release for decades. A one off procedure would be more favourable than many less 687 
effective ones over the course of a lifetime.[129,130]   688 
Executive summary: 689 
Strategies to enhance the bioavailability of drugs are; 690 
Drug solubility and penetration enhancement 691 
 Many ocular drugs have low aqueous solubility; this can be improved using hydrotropic 692 
compounds. Formulating for higher drug concentration means increased availability. 693 
 Inclusion of penetration enhancers within a formulation improves drug partitioning into 694 
tissue.  695 
          Drug retention strategies 696 
 Viscosity enhancing polymers, in situ gels and bioadhesives allow eye drop formulation 697 
to resist pre-corneal losses and they retain intimate contact with ocular tissue longer 698 
giving the dose form more time to penetrate ocular membranes.   699 
 Drug delivery from ocular inserts are a means to place the dose form in immediate 700 
contact with ocular mucosa, this strategy allows controlled and sustained drug release for 701 
an extended period. 702 
           Ocular implants 703 
 Implantable devices are designed to penetrate the ocular membranes or reside entirely 704 
within the eye. This strategy overcomes all external barriers and can offer short term 705 
medication or deliver medication for several years when treating chronic conditions. 706 
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           Future perspectives 707 
 A speculative outlook considered the possibility of innovative technologies developing 708 
synthetic tissues to enable testing new drugs and possibly even produce artificial corneas 709 
for transplant. The idea of developing novel materials for vitreous humour replacement as 710 
lifetime drug delivery depots could potentially become realised. 711 
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